Japan’s Ministry of Health, Labor and Welfare (MHLW) has accepted UK pharma major GSK’s (LSE: GSK) regulatory application to expand the use of its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine to include adults aged 18 to 49 years at increased risk of severe RSV disease.
Arexvy was the first vaccine approved in Japan for adults aged 60 years and older for the prevention of RSV disease, and for those aged 50 years and older at increased risk for severe RSV disease.
The London-based drugmaker’s regulatory submission to the MHLW is supported by positive results from a Phase IIIb trial, which showed a non-inferior immune response in adults aged 18 to 49 years at increased risk for RSV-LRTD due to certain underlying medical conditions, to that observed in adults aged 60 and above.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze